Challenges mount for vaccine makers

End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump administration.

By Amy Baxter • Feb. 19, 2025

Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split

The two companies will let their long-running contract expire this year, and drugmakers will need to decide which is the best platform for them in a changing marketplace.

By Michael Gibney • Feb. 13, 2025

The kids are alright: How pharma can make inroads with Gen Z

As drug development priorities shift, pharma companies need to understand younger patients to improve their reputation.

By Amy Baxter • Feb. 12, 2025

Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments

Fractyl Health is entering pivotal studies for a procedure that aims to be an ‘off ramp’ to GLP-1s and exploring how a one-time, ‘smart GLP-1’ gene therapy can Treat type 2 diabetes.

By Amy Baxter • Feb. 10, 2025

Bristol Myers gives first peek at closely watched launch of schizophrenia drug

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the fourth quarter and around 1,000 prescriptions weekly by late January.

By Jacob Bell • Feb. 7, 2025

With uncertainty roiling Big Pharma, execs are placing lower-risk bets

The market has been no less demanding for pharma giants as 2025 begins, but last year’s strategies are paying off.

By Michael Gibney • Feb. 6, 2025

Executive hiring changes reflect a broader biotech comeback

Executive hiring shifts are often indicators of wider trends in the market. Here’s how the hiring landscape for pharma leaders is changing.

By Alexandra Pecci • Jan. 29, 2025

Innovate or perish: Industry’s evolution leaves little room for me-too approaches

Novel drug approvals have set the stage for more breakthroughs in pharma.

By Amy Baxter • Updated Jan. 22, 2025

In pharma’s competitive climate, companies need evidence beyond clinical trials

Early planning and market research are crucial in an era of rising cost pressures.

By Kelly Bilodeau • Jan. 21, 2025

Merck is broadening its pipeline as Keytruda’s patent cliff looms

Merck looks ahead with an array of cardiometabolic, immunology, neuroscience and ophthalmology pipelines.

By Alexandra Pecci • Jan. 14, 2025

The ability to pivot will be ‘key’ as pharma’s tariff threat looms

Companies are looking to new countries like Vietnam for manufacturing needs, but change comes at a cost.

By Kelly Bilodeau • Jan. 13, 2025

PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials

Coming changes that could impact pharma from drug development to launch.

By Meagan Parrish • Jan. 10, 2025

10 of our most read articles of 2024

The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.

By Meagan Parrish • Dec. 20, 2024

Zepbound, Mounjaro shortages are resolved, FDA confirms

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.

By Ned Pagliarulo • Dec. 20, 2024

Big Pharma’s new DTC play: partnering with digital health providers

The pharma giant is looking for another edge in the competitive weight loss market through DTC expansion.

By Amy Baxter • Dec. 18, 2024

A drug for fewer than 1,000 patients? Awareness and diagnosis are key.

Zevra Therapeutics is building a commercial strategy for an ultra-small patient pool.

By Amy Baxter • Dec. 9, 2024

How Alexion markets a rare disease drug by ‘starting with the end in mind’

The biopharma, now an arm of AstraZeneca, needs to build the plane while flying it to be first in rare diseases with no other option.

By Michael Gibney • Dec. 3, 2024

Left to clean up after ‘pharma bro’ Shkreli’s arrest, former Turing CEO Ron Tilles reckons with the past

While Martin Shkreli smirked his way through a public securities fraud investigation, Ron Tilles became interim CEO of Turing Pharmaceuticals, ready or not. Here’s his story.

By Michael Gibney • Nov. 14, 2024

From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies

As the industry’s marketing dollars shift, companies are targeting potential patients in unique ways.

By Amy Baxter • Nov. 13, 2024

Pfizer and Lilly’s telehealth prescribing platforms draw Senate scrutiny for ‘potential fraud’

As Big Pharma embraces telehealth to sell medicines directly to patients, lawmakers wonder whether the programs skirt anti-kickback rules.

By Kelly Bilodeau • Nov. 12, 2024

Big Pharma earnings hang hope on the next generation of blockbusters

Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.

By Michael Gibney • Oct. 31, 2024

Backlash builds against Novo’s Catalent takeover

Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug market.

By Amy Baxter • Oct. 30, 2024

2024 PharmaVoice 100s: Rare Disease Warriors

Pharma pros driving drug development and access for patients with high unmet needs. 

By Meagan Parrish • Oct. 29, 2024

J&J’s comeback kid Spravato heads for blockbuster status

After a slow start, the novel esketamine nasal spray for depression is now J&J’s fastest-growing medication.

By Meagan Parrish • Oct. 25, 2024

Dengue is spreading and Sanofi is pulling the U.S. market’s only vaccine. What’s next?

As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.

By Alexandra Pecci • Oct. 23, 2024